LRRC8A and ovarian carcinoma: The potential relevance to the treatment of human cancer is suggested by our finding that patients with ovarian cancer as well as HNSCC with low gene expression levels of LRRC8A or LRRC8D in their tumors have a reduced benefit of Pt-based chemotherapy.